Research

Gyroscope Therapeutics Files Registration Statement for Proposed Initial Public Offering in the United States

Friday, April 16, 2021 - 10:38pm

b'Gyroscope Therapeutics, a clinical-stage gene therapy company focused on treating diseases of the eye, today announced it has filed a registration statement on Form F-1 (the \xe2\x80\x9cRegistration Statement\xe2\x80\x9d) with the U.S. Securities and Exchange Commission (the \xe2\x80\x9cSEC\xe2\x80\x9d) relating to a proposed initial public offering (\xe2\x80\x9cIPO\xe2\x80\x9d) in the United States of its American Depositary Shares (\xe2\x80\x9cADSs\xe2\x80\x9d), each representing one ordinary share.\nAll ADSs to be sold in the proposed IPO will be offered by Gyroscope.

Key Points: 
  • b'Gyroscope Therapeutics, a clinical-stage gene therapy company focused on treating diseases of the eye, today announced it has filed a registration statement on Form F-1 (the \xe2\x80\x9cRegistration Statement\xe2\x80\x9d) with the U.S. Securities and Exchange Commission (the \xe2\x80\x9cSEC\xe2\x80\x9d) relating to a proposed initial public offering (\xe2\x80\x9cIPO\xe2\x80\x9d) in the United States of its American Depositary Shares (\xe2\x80\x9cADSs\xe2\x80\x9d), each representing one ordinary share.\nAll ADSs to be sold in the proposed IPO will be offered by Gyroscope.
  • Gyroscope has applied to list its ADSs on the Nasdaq Global Select Market under the ticker symbol \xe2\x80\x9cVISN.\xe2\x80\x9d The number of ADSs to be offered and the pricing terms for the proposed IPO have not yet been determined.
  • The ADSs may not be sold nor may offers to buy be accepted prior to the time the Registration Statement becomes effective.
  • Headquartered in London with locations in Philadelphia and San Francisco, our mission is to preserve sight and fight the devastating impact of blindness.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210416005566/en/\n'

OKR Financial Raises $150 Million to Support Early-Stage Innovators With Immediate Capital

Friday, April 16, 2021 - 6:53pm

b'OKR Financial, one of Canada\xe2\x80\x99s leading providers of non-dilutive financing, is announcing its raise of $150 million to support growing businesses looking to access SR&ED tax credits, asset-based loans, government grants, or equity deals.

Key Points: 
  • b'OKR Financial, one of Canada\xe2\x80\x99s leading providers of non-dilutive financing, is announcing its raise of $150 million to support growing businesses looking to access SR&ED tax credits, asset-based loans, government grants, or equity deals.
  • Solving the problem of waiting for government agencies to process tax claims or grant applications, OKR Financial\xe2\x80\x99s help allows companies to access funding fast, extending the runway so these companies can continue to grow while they await their government funds.\nThe OKR team has strategically chosen to partner with Ayming Canada, a global consulting firm which helps businesses maximize government funding and tax credits.
  • This is where Ayming\xe2\x80\x99s expertise comes in,\xe2\x80\x9d says Harry Singh, President & Managing Partner of Ayming Canada.\nThe Scientific Research & Experimental Development (SR&ED) Tax Credit program provides over $3 billion to over 20,000 businesses annually, and there are over 2000 various government grants available, with more being announced all the time.
  • OKR operates a family of private funds that provide non-dilutive financing solutions to SMEs by leveraging Federal & Provincial SR&ED tax credits and Government funded programs, providing the pathway to equity financing when companies are ready to scale up.\n'

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma....

Friday, April 16, 2021 - 6:10pm

In patients receiving OPDIVO monotherapy, immune-mediated colitis occurred in 2.9% (58/1994) of patients, including Grade 3 (1.7%) and Grade 2 (1%).\nOPDIVO can cause immune-mediated hepatitis.

Key Points: 
  • In patients receiving OPDIVO monotherapy, immune-mediated colitis occurred in 2.9% (58/1994) of patients, including Grade 3 (1.7%) and Grade 2 (1%).\nOPDIVO can cause immune-mediated hepatitis.
  • Withhold OPDIVO depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information).
  • In patients receiving OPDIVO monotherapy as a 60-minute infusion, infusion-related reactions occurred in 6.4% (127/1994) of patients.
  • Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: first results of the CheckMate 649 study.

2020 Report on Insulin Resistance R&D Pipeline Analysis - Small Insulin Resistance Companies Look for Licensing and Collaboration Partners - ResearchAndMarkets.com

Friday, April 16, 2021 - 6:00pm

b'The "Insulin Resistance R&D Pipeline Analysis Report, Q4 2020" report has been added to ResearchAndMarkets.com\'s offering.\nThe Q4 Insulin Resistance pipeline report is part of the VPA Metabolic Disorder disease pipeline service.

Key Points: 
  • b'The "Insulin Resistance R&D Pipeline Analysis Report, Q4 2020" report has been added to ResearchAndMarkets.com\'s offering.\nThe Q4 Insulin Resistance pipeline report is part of the VPA Metabolic Disorder disease pipeline service.
  • This quarterly review describes the pipeline of drugs under development for Insulin Resistance, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.\nThe comprehensive report on the indication presents Insulin Resistance disease overview, Insulin Resistance types, Insulin Resistance symptoms, causes, and FDA/EMA approved treatment options.\nThe year 2020 witnessed progress in innovations and the number of pipeline agents researched for Insulin Resistance indication.
  • The report presents near-term and long-term pipeline development trends and potential insights.\nThe report analyzes the development progress, current status, investments, partnerships, and other developments of 8 companies.
  • Further, the presence of large companies and stringent regulations act as barriers for Insulin Resistance pipeline development companies.

Global Super-resolution Microscopes Market Report 2021: Technology, Application, End-User, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis 2020-2025 - ResearchAndMarkets.com

Friday, April 16, 2021 - 5:38pm

Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments and growth in market share.\nThe report offers a comprehensive evaluation of the Global Super-resolution Microscopes Market.

Key Points: 
  • Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments and growth in market share.\nThe report offers a comprehensive evaluation of the Global Super-resolution Microscopes Market.
  • The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size.\nThe projections are calculated using proven research methodologies.\nThe report has been compiled through extensive primary and secondary research.
  • The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.\nThe report includes in-depth market analysis using Porter\'s 5 force model and the Ansoff Matrix.
  • The impact of Covid-19 on the market is also featured in the report.\n'

Aegis Life Announces Start of Phase 1/2 Trial of the Entos COVID-19 DNA Vaccine, Covigenix VAX-001, with First Participants Dosed

Friday, April 16, 2021 - 5:26pm

b'Aegis Life, Inc. announced today that the first participants have been dosed in a Phase 1/2 clinical trial with parent company Entos Pharmaceuticals\xe2\x80\x99 (Entos) Covigenix VAX-001, a novel DNA vaccine to stimulate immunity against SARS-CoV-2.

Key Points: 
  • b'Aegis Life, Inc. announced today that the first participants have been dosed in a Phase 1/2 clinical trial with parent company Entos Pharmaceuticals\xe2\x80\x99 (Entos) Covigenix VAX-001, a novel DNA vaccine to stimulate immunity against SARS-CoV-2.
  • View the full release here: https://www.businesswire.com/news/home/20210416005430/en/\nA participant receives a dose marking the start of Phase I trials for Aegis Life/Entos Pharmaceuticals COVID-19 DNA vaccine, Covigenix VAX-001.
  • Phase 1 will evaluate the safety and immunogenicity of the Covigenix VAX-001 DNA vaccine.
  • This breakthrough non-viral gene delivery platform allows us to rapidly prototype and advance DNA medicines through the clinical trial process.

Global Laboratory Product Purchasing Trends Report 2020-2021 - ResearchAndMarkets.com

Friday, April 16, 2021 - 11:47am

b'The "Global Laboratory Product Purchasing Trends, 2020-2021" report has been added to ResearchAndMarkets.com\'s offering.\nReaders of one of the publisher\'s media partners were invited to participate in an online survey in September 2020 that centered on the state of their laboratories in 2020 and their expectations for 2021.\nThe publisher has conducted similar studies among the same targeted respondents since 2012.

Key Points: 
  • b'The "Global Laboratory Product Purchasing Trends, 2020-2021" report has been added to ResearchAndMarkets.com\'s offering.\nReaders of one of the publisher\'s media partners were invited to participate in an online survey in September 2020 that centered on the state of their laboratories in 2020 and their expectations for 2021.\nThe publisher has conducted similar studies among the same targeted respondents since 2012.
  • Biotechnology, pharmaceutical, and contract research organization are combined as biopharmaceutical laboratories.\nState government and federal government laboratories are combined as government laboratories.
  • Hospital laboratories and clinical reference laboratories fall under the clinical segment.
  • Respondents indicated a wide range of job titles including researcher, scientist, investigator, director, manager, and technician.\n'

Oregon Oncology Specialists Integrate AI-screening Solution VIPER™ Into Network to Expand Patient Access to Clinical Trials

Friday, April 16, 2021 - 3:05pm

b'Deep Lens and Oregon Oncology Specialists today announced a strategic collaboration that will integrate Deep Lens\xe2\x80\x99 artificial-intelligence (AI)-based clinical trial screening platform, VIPER\xe2\x84\xa2, into their community oncology practice network.

Key Points: 
  • b'Deep Lens and Oregon Oncology Specialists today announced a strategic collaboration that will integrate Deep Lens\xe2\x80\x99 artificial-intelligence (AI)-based clinical trial screening platform, VIPER\xe2\x84\xa2, into their community oncology practice network.
  • VIPER uses proprietary cloud-based technology to facilitate, triage and accelerate the clinical trial recruitment process.
  • Limited site capacity and resources play a role in the challenge to recruit and enroll, as well as low patient engagement.
  • Today, Oregon Oncology Specialists is composed of eight physicians and ten advanced practice providers and serves patients in four locations in Oregon (Salem, McMinnville, Silverton and Woodburn).

New Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology

Friday, April 16, 2021 - 1:00pm

b'Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new pooled data from the TEPEZZA\xc2\xae (teprotumumab-trbw) Phase 2 and Phase 3 clinical trials are now published in The Lancet Diabetes & Endocrinology .

Key Points: 
  • b'Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new pooled data from the TEPEZZA\xc2\xae (teprotumumab-trbw) Phase 2 and Phase 3 clinical trials are now published in The Lancet Diabetes & Endocrinology .
  • The data further reinforce that TEPEZZA significantly improves proptosis (eye bulging) and diplopia (double vision) for TED patients in different subgroups, with most maintaining a long-term response.
  • Responses were also evaluated at seven weeks and 51 weeks after the final dose of TEPEZZA.
  • In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia.

Castle Biosciences Presents Data at the 10th World Congress of Melanoma and 17th European Association of Dermato-Oncology Congress

Friday, April 16, 2021 - 12:00pm

Castle presented data on DecisionDx-SCC with two virtual posters.

Key Points: 
  • Castle presented data on DecisionDx-SCC with two virtual posters.
  • Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need.
  • Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona.
  • Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make.